Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies

  • Anastasios T Dimou Department of Pathology, Yale University School of Medicine. New Haven, CT, USA
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, University of Athens. Athens, Greece
  • Muhammad Wasif Saif Columbia University College of Physicians and Surgeons and Pancreas Center, New York Presbyterian Hospital. New York, NY, USA
Keywords: adverse effects, Clinical Trials, Phase I as Topic, Mitogen-Activated Protein Kinase Kinases, Pancreatic Neoplasms

Abstract

Pancreatic adenocarcinoma has repetitively proved refractory to chemotherapy and biologic compounds with only a few drugs offering limited benefit. A number of novel regimens has been tested in phase I trials and reported recently in the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Specifically, a novel mitogen-activated protein kinase kinase (MEK) inhibitor, a connective tissue growth factor inhibitor, a coagulase factor VIIa inhibitor, as well as adenovirus delivery of herpes simplex virus thymidine synthase gene followed by anti-herpetic treatment have all proven to be safe in pancreatic cancer patients. Phase II trials will provide further evidence whether they can become clinically relevant in the future.

Image: Yale University School of Medicine. New Haven, CT, USA (logo).

Downloads

Download data is not yet available.

References

Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17. [PMID 20427809]

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]

Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011;12:8-9. [PMID 21050812]

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54. [PMID 2453289]

Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6:1186-97. [PMID 17406031]

Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-22. [PMID 20606091]

Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834-8. [PMID 19738116]

Tolcher AW, Bendell JC, Patnaik A, Papadopoulos K, Bellew KM, Cox DS, Xu Y, et al. A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011; 29(Suppl. 4):Abstract 278.

Heestand GM, Pipas JM, Valone F, McMullen AD, Gadea P, Williams D, Zhong M, et al. A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 269.

Ramanathan RK, Gressler V, Shah S, Loury D, Hamdy A, Khorana A. Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor in patients with advanced pancreatic cancer receiving treatment with gemcitabine. J Clin Oncol 2011; 29(Suppl. 4):Abstract 221.

Bloomston M, Marsh C, Walker J, Coyle W, Marx H, Tahiri S, et al. Phase I trial of gene-mediated cytotoxic immunotherapy in combination with chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 195.

Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-62. [PMID 15483017]

Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17:989-1000. [PMID 21245089]

Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010; 5:1420-8. [PMID 20522536]

Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11:2197-205. [PMID 11084677]

Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23:7927-35. [PMID 16258092]

Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, Song Y, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13:5847-54. [PMID 17908978]

Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009;16:723-30. [PMID 19363470]

Yale University School of Medicine. New Haven, CT, USA (logo)
Published
2011-03-09
How to Cite
DimouA., SyrigosK., & SaifM. (2011). Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. JOP. Journal of the Pancreas, 12(2), 114-116. https://doi.org/10.6092/1590-8577/3335
Section
Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20-22, 2011